AUSTRALASIA
One of the largest pharmaceutical companies in the Australasia region, with a comprehensive portfolio of medicines comprising Regional Brands, including prescription and over-the-counter products, as well as Sterile Focus Brands. A widely-accredited manufacturing facility is operated in Australia, producing finished dose form (“FDF”) solids, liquids and semi-solids as well as packaging for third party contract manufacturing for domestic and export markets.
Key Countries
Australia
New Zealand
KEY BRANDS
Brand | Therapeutic category | |
Circadin | Sleeping aid | |
Eltroxin/Eutroxsig/Oroxine | Thyroid hormone replacement range |
|
Maltofer | Iron supplement | |
Ural | Womens’ health | |
Xylocaine & Adrenaline |
Regional anaesthetic |
NUMBER OF PERMANENT EMPLOYEES
538
June 2021
531
June 2020

STATISTICS
Number of products launched:
2
(2020: 2)
Number of product recalls:
Nil
(2020: 2)
Average staff turnover:
8%
(2020: 9%)
Number of work-related fatalities:
Nil
(2020: Nil)
Sales representatives:
74
(2020: 70)
Revenue | 2021 R’million |
2020 (CER) R’million |
Change % |
||||
---|---|---|---|---|---|---|---|
Total Commercial Pharmaceuticals | 4 867 | 4 623 | 5 | ||||
Regional Brands | 4 113 | 3 876 | 6 | ||||
Sterile Focus Brands | 754 | 747 | 1 | ||||
Manufacturing – FDF | 554 | 430 | 29 | ||||
Total | 5 421 | 5 053 | 7 |
Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.
- The Australian and New Zealand pharmaceutical market combined, grew 1,9% and was valued at AUD20,7 billion MAT* to May 2021.
Source: IQVIA – August 2020
*MAT = Moving annual total